Brief: Acurx Announces Positive Comparative Microbiology And Microbiome Data For Ibezapolstat From Phase 2b Clinical Trial In CDI Patients
17/01/2024 12:25
Jan 17 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX ANNOUNCES POSITIVE COMPARATIVE MICROBIOLOGY AND
MICROBIOME
DATA FOR IBEZAPOLSTAT FROM PHASE 2B CLINICAL TRIAL IN CDI
PATIENTS
* ACURX PHARMACEUTICALS - IBEZAPOLSTAT OUTPERFORMED
VANCOMYCIN
SHOWING ERADICATION OF FECAL C. DIFFICILE AT DAY 3 OF TREATMENT
IN 15 OF 16 PATIENTS
* ACURX PHARMACEUTICALS INC - PREPARATION UNDERWAY FOR
MEETINGS
WITH FDA, EMA, OTHER GLOBAL REGULATORY AGENCIES
* ACURX PHARMACEUTICALS INC: IBEZAPOLSTAT, BUT NOT
VANCOMYCIN,
CONSISTENTLY PRESERVED AND ALLOWED REGROWTH OF KEY GUT BACTERIAL
SPECIES
* ACURX PHARMACEUTICALS INC - PREPARATION UNDERWAY FOR
ADVANCEMENT TO INTERNATIONAL PHASE 3 CLINICAL TRIALS
* ACURX PHARMACEUTICALS INC - FURTHER ANALYSES WILL BE
FORTHCOMING
Q1 2024 REGARDING OTHER ENDPOINTS FROM PHASE 2B TRIAL
Source text for Eikon: ID:nPn3HBfTva
Further company coverage: ACXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acurx Pharmaceuticals
See all newsAcurx Pharmaceuticals Q1 net loss narrows as expenses fall
Brief: Acurx Pharmaceuticals To Discuss First Quarter 2026 Financial Results On May 12, 2026 Conference Call And Provide Business Update
Brief: Acurx Pharmaceuticals, Inc. Announces Closing Of Up To $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend
Acurx Pharma Q3 net loss narrows to $2 mln